Kevin P. Clark has been a director since March 2015, when he became Aptiv’s President and Chief Executive Officer. In April 2022, he was named Chair and Chief Executive Officer.
In 2014, Mr. Clark was appointed Chief Operating Officer responsible for Aptiv’s business segments, as well as the global supply chain function. He joined Aptiv in 2010 as Chief Financial Officer, responsible for all financial activities, including strategic planning, corporate development, financial planning and analysis, treasury, accounting, and tax.
Before joining Aptiv, he was a founding partner of Liberty Lane Partners, LLC, a private investment company with investment holdings in healthcare, technology and distribution-related industries from 2007 to 2010. He served as Chief Financial Officer of Fisher Scientific International Inc., a manufacturer, distributor and service provider to the global healthcare market, from the company’s initial public offering in 2001 through the completion of its merger with Thermo Electron Corporation in 2006 forming Thermo Fisher Scientific Inc.. He also held a number of senior management positions while at Fisher Scientific. He began his career in the financial organization of Chrysler Corporation.
Mr. Clark has both a bachelor’s degree in financial administration and a master’s degree in finance from Michigan State University.
What is Kevin P. Clark's net worth?
The estimated net worth of Kevin P. Clark is at least $9.24 million as of September 8th, 2026. Mr. Clark owns 198,979 shares of Versigent stock worth more than $9,242,973 as of September 11th. This net worth evaluation does not reflect any other assets that Mr. Clark may own. Learn More about Kevin P. Clark's net worth.
How do I contact Kevin P. Clark?
Has Kevin P. Clark been buying or selling shares of Versigent?
During the last ninety days, Kevin P. Clark has sold $5,718,904.94 of Versigent stock. Most recently, Kevin P. Clark sold 74,130 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $45.67, for a transaction totalling $3,385,517.10. Following the completion of the sale, the director now directly owns 124,849 shares of the company's stock, valued at $5,701,853.83. Learn More on Kevin P. Clark's trading history.
Are insiders buying or selling shares of Versigent?
In the last twelve months, insiders at the sold shares 2 times. They sold a total of 122,722 shares worth more than $5,718,904.94. The most recent insider tranaction occured on September, 9th when Director
Kevin P. Clark sold 74,130 shares worth more than $3,385,517.10.
Learn More about insider trades at Versigent. Information on this page was last updated on 9/9/2026.
